Back
Halozyme Therapeutics Quote, Financials, Valuation and Earnings
Write This Down: Tuesday at 2 p.m. ET!
Don't Miss Our LIVE Trade
Buy
72
HALO
Halozyme Therapeutics
Last Price:
57.96
Seasonality Move:
16.49%
7 Day Trial
ALL ACCESS PASS
$
7
The Mysterious VC Firm Behind Nvidia's Secret Weapon
Details Here!Halozyme Therapeutics Price Quote
$57.96
-0.50 (-0.86%)
(Updated: November 5, 2024 at 2:35 PM ET)
Halozyme Therapeutics Key Stats
Buy
72
Halozyme Therapeutics (HALO)
is a Buy
Day range:
$56.82 - $59.39
52-week range:
$33.15 - $65.53
Dividend yield:
0%
P/E ratio:
27.84
P/S ratio:
8.01
P/B ratio:
16.43%
Volume:
1.9M
Avg. volume:
1.4M
1-year change:
64.31%
Market cap:
$7.4B
Revenue:
$829.3M
EPS:
$3.02
How Much Does Halozyme Therapeutics Make?
-
How Much Are Halozyme Therapeutics's Sales Annually?
HALO Revenues are $829.3M -
How Much Profit Does Halozyme Therapeutics's Make A Year?
HALO net income is $281.6M
Is Halozyme Therapeutics Growing As A Company?
-
What Is Halozyme Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.34% -
What Is Halozyme Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0.72%
Halozyme Therapeutics Stock Price Performance
-
Did Halozyme Therapeutics Stock Go Up Last Month?
Halozyme Therapeutics share price went down by -1.22% last month -
Did HALO's Share Price Rise Over The Last Year?
HALO share price rose by 64.31% over the past 1 year
What Is Halozyme Therapeutics 52-Week High & Low?
-
What Is Halozyme Therapeutics’s 52-Week High Share Price?
Halozyme Therapeutics has traded as high as $65.53 over the past 52 weeks -
What Is Halozyme Therapeutics’s 52-Week Low Share Price?
Halozyme Therapeutics has traded as low as $33.15 over the past 52 weeks
Halozyme Therapeutics Price To Free Cash Flow
-
Is Halozyme Therapeutics Stock Overvalued?
Halozyme Therapeutics is trading at a price to free cash flow ratio of 19.33 -
Is Halozyme Therapeutics Stock Undervalued?
Halozyme Therapeutics EV to Free Cash Flow ratio is 21.07 -
What Is Halozyme Therapeutics’s Price Earnings Growth Ratio?
HALO PEG ratio is 0.32 -
Is Halozyme Therapeutics Trading At A Premium To Earnings?
Halozyme Therapeutics EV to EBIT ratio is 16.59
Is It Risky To Buy Halozyme Therapeutics?
-
How Much Debt Does Halozyme Therapeutics Have?
Total long term debt quarterly is $1.5B -
How Much Cash Does Halozyme Therapeutics Have?
Cash and short term investments quarterly total is $666.3M -
What Is Halozyme Therapeutics’s Book Value Per Share?
Book value per share is 3.56
Is Halozyme Therapeutics Cash Flow Positive?
-
What Is HALO Cash Flow From Operations?
Cash flow from operations (TTM) is $403M -
What Is Halozyme Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$222.4M -
What Is Halozyme Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$300.5M
Halozyme Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
HALO return on invested capital is 22.41% -
What Is Halozyme Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is 20.54% -
What Is HALO Return On Equity?
ROE is a measure of profitability and is 156.62%
Halozyme Therapeutics Earnings Date & Stock Price
-
What Is Halozyme Therapeutics's Stock Price Today?
A single share of HALO can be purchased today for 58.46 -
What Is Halozyme Therapeutics’s Stock Symbol?
Halozyme Therapeutics trades on the nasdaq under the ticker symbol: HALO -
When Is Halozyme Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Halozyme Therapeutics is scheduled on February 20, 2025 -
When Is HALO's next ex-dividend date?
Halozyme Therapeutics's next ex-dividend date is November 5, 2024 -
How To Buy Halozyme Therapeutics Stock?
You can buy Halozyme Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Halozyme Therapeutics Competitors
-
Who Are Halozyme Therapeutics's Competitors?
Below is a list of companies who compete with Halozyme Therapeutics or are related in some way:
Halozyme Therapeutics Dividend Yield
-
What Is HALO Dividend Yield?
Halozyme Therapeutics’s dividend yield currently is 0% -
What Is Halozyme Therapeutics’s Payout Ratio?
Halozyme Therapeutics’s payout ratio is 0% -
When Did Halozyme Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 5, 2024 -
What Is Halozyme Therapeutics’s Dividend Per Share?
Halozyme Therapeutics pays a dividend of $0.00 per share
Halozyme Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 72.13% | 27.05% |
| Revenue: | 34.28% | 15.04% |
Analyst Recommendations
| Buy Recommendations: | 3 |
|---|---|
| Hold Recommendations: | 5 |
| Sell Recommendations: | 0 |
| Price Target: | 62.60 |
| Upside from Last Price: | 7.08% |